MAIA Biotechnology Secures European Patent for Novel Cancer Therapies

Strategic Insights -

MAIA Biotechnology, a clinical-stage biopharmaceutical company, has announced that the European Patent Office has granted a patent covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy. This patent is the result of the innovative work of MAIA's Chief Scientific Officer Sergei M. Gryaznov, PhD, and Scientific Advisory Board member Jerry W. Shay, PhD. The new compounds are designed to disrupt the structure and function of telomeres, interfering with the growth of cancer cells and causing programmed cancer cell death.

Key Takeaways:

  • The European Patent Office has granted a patent covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy, broadening MAIA's innovative cancer treatment platform.
  • The new compounds, invented by Sergei M. Gryaznov, PhD, and Jerry W. Shay, PhD, disrupt the structure and function of telomeres, reducing immune system activity and interfering with cancer cell growth.
  • The patent is expected to further secure and expand the value of MAIA's first-in-class telomere-targeting compounds across the European scientific community.
  • MAIA's global patent and patent-pending estate covers several areas, including telomerase mediated telomere altering compounds and treatment of therapy-resistant cancers.
  • Ateganasine's immunogenic treatment strategy, which focuses on sequential combination with checkpoint inhibitors, has been filed worldwide.
  • MAIA's IP portfolio for ateganosine comprises 10 issued patents worldwide, including Europe, and 24 pending patent applications.

Statistics:

  • 19 countries in Europe have validated the patent.
  • MAIA's IP portfolio for ateganosine includes 10 issued patents worldwide and 24 pending patent applications.
  • The company's global patent and patent-pending estate covers several areas, with a focus on telomerase mediated telomere altering compounds and therapy-resistant cancers.

Sources:

  • MAIA Biotechnology, Inc. (NYSE American: MAIA) news release, [no date specified]